Thursday, April, 18, 2019 08:36:58

AusCann signs deal with MediPharm Labs to purchase cannabis resin

The latest move underlines MediPharm’s first international export deal. AusCann Group Holdings Ltd. (AC8), an Australian cannabis medicine company, has reportedly entered into a supply agreement with the leading cannabis extractor in Canada, MediPharm Labs Corp., for the purchase of cannabis resin. AusCann, for the …

Reata announces positive results from bardoxolone phase 2 study

The study specifies the possibility of preventing or delaying kidney failure and the need for dialysis or a kidney transplant in patients with rare chronic kidney disease. U.S. clinical-stage biopharmaceutical firm, Reata Pharmaceuticals, Inc. has recently announced its final, positive result from the focal segmental …

Diploid & Genomenon team up to advance rare disease diagnostics

In a major effort to develop genome interpretation for the rare disease diagnostics, Genomenon, a top genomic research company, and Diploid, a prominent AI-based software company for rare disease diagnostics, have reportedly inked a partnership deal. Sources with the knowledge of the matter stated that …

FDA permits Priority Review for Roche’s drug Polatuzumab Vedotin

The FDA will decide on the definitive approval by the 19th of August 2019. The U.S. Food & Drug Administration (FDA) has reportedly accepted the BLA (Biologics License Application) submitted by the Swiss multinational healthcare company, Roche. The company has been officially granted Priority Review …

Innovent, Chipscreen Biosciences team up on colorectal cancer therapy

Shenzhen Chipscreen Biosciences Ltd., a leading China-based integrated biotech company, has reportedly entered into a collaboration agreement with Innovent Biologics Inc., a Chinese development-stage biopharmaceutical company, in a major effort to evaluate the tolerability and safety of the combination therapy involving Innovent’s Sintilimab and Chipscreen’s …